Precigen, Inc. (PGEN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
Research Workspace
Put PGEN beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisManagement screens strong on capital allocation, market reaction to earnings.
View ManagementThis stock is volatile — it swings about 3% on a typical day and fell roughly 51% in its worst 12-month stretch.
View RiskPrecigen's Papzimeos growth has to keep compounding to justify the price. Revenue grew 54% year over year in the latest quarter. The company also beat its earnings estimate. It trades at 26 times sales versus an 8.8 times peer median. The price is roughly in line with the growth we forecast. A new FDA-approved rival now threatens its market share. Our model puts the next-quarter miss probability near 48%. Peer multiples imply a price about 103% below where it trades. Our read remains intact. This read is provisional.
End-of-day figures as of 2026-11-05. EPS is implied from price ÷ P/E. Not investment advice.
Trailing returns as of 2026-11-05. PGEN is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 4 analysts currently covering PGEN (as of Nov 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare PGEN with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| PGEN Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 3 valuation methods, at three horizons. As of 2026-11-05. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put PGEN next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Expand PAPZIMEOS commercial adoption and patient access
Analyst upgrade confirms strong Q3 topline and commercial momentum.

Advances: Expand PAPZIMEOS commercial adoption and patient access
Analyst upgrade confirms strong sales, supporting commercial adoption.

Advances: Expand PAPZIMEOS commercial adoption and patient access
Positive outlook on Papzimeos supports commercial adoption objective.

Advances: Achieve cash flow break-even by end of 2026
Significant revenue growth supports cash flow break-even goal.

FDA approval supports product launch and revenue potential.
CFO's stock sale raises concerns about leadership stability.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.